Usmani, Saad Z. http://orcid.org/0000-0002-5484-8731
Mateos, Maria-Victoria
Hungria, Vania
Iida, Shinsuke
Bahlis, Nizar J.
Nahi, Hareth
Magen, Hila
Cavo, Michele
Hulin, Cyrille
White, Darrell
De Stefano, Valerio
Fastenau, John
Slavcev, Mary
Heuck, Christoph
Qin, Xiang
Pei, Huiling
Masterson, Tara
Lantz, Kristen
Gries, Katharine S.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Pharmacodynamic-Mediated Drug Disposition (PDMDD) Model of Daratumumab Monotherapy in Patients with Multiple Myeloma
https://doi.org/10.1007/s40262-023-01232-8
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results
https://doi.org/10.1007/s00432-020-03365-w
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Funding for this research was provided by:
Janssen Research and Development
Article History
Received: 26 June 2020
Accepted: 18 August 2020
First Online: 27 August 2020
Compliance with ethical standards
:
: SZU received research funding from Amgen, Array Biopharma, Bristol-Myers Squibb, Celgene, Janssen Pharmaceuticals, Merck, Pharmacyclics, Sanofi, and Takeda; consulted for Amgen, Bristol-Myers Squibb, Celgene, Janssen Pharmaceuticals, Merck, SkylineDx, and Takeda; and served on speakers bureaus for Amgen, Celgene, Janssen Pharmaceuticals, Sanofi, and Takeda. M-VM received honoraria from Adaptive Biotechnologies, Amgen, Celgene, Janssen Pharmaceuticals, and Takeda; served on the Board of Directors or advisory committees for AbbVie, Amgen, Celgene, GenTech, GlaxoSmithKline, Janssen Pharmaceuticals, Mundipharma, PharmaMar, Roche, and Takeda; served on data and monitoring committees for Amgen and Janssen Pharmaceuticals; and served on speakers bureaus for Amgen, Celgene, Janssen Pharmaceuticals, and Takeda. VH consulted and served on speakers bureaus for, and received honoraria from, Amgen, Bristol-Myers Squibb, Celgene, Janssen Pharmaceuticals, and Takeda. SI received honoraria and research funding from Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Janssen Pharmaceuticals, Ono, Sanofi, and Takeda; and research funding from AbbVie, Chugai, Kyowa Kirin, and Merck Sharp & Dohme. NJB consulted for and received honoraria from AbbVie, Amgen, Celgene, Janssen Pharmaceuticals, and Takeda. MC consulted for AbbVie, Amgen, Celgene, and Janssen Pharmaceuticals; received honoraria from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen Pharmaceuticals, and Takeda; and served on speakers bureaus for and received travel and/or accommodation expenses from Celgene and Janssen Pharmaceuticals. CH received honoraria from AbbVie, Amgen, and Celgene. DW consulted for and received honoraria from Amgen, Celgene, Janssen Pharmaceuticals, Sanofi, and Takeda. VDS served on advisory boards for Amgen, Celgene, Janssen-Cilag, and Novartis. JF, MS, CH, XQ, HP, TM, KL, and KSG are employees of Janssen Pharmaceuticals. HN and HM have no conflicts to disclose.
: The COLUMBA study was done in accordance with the principles of the Declaration of Helsinki, International Conference on Harmonisation Guideline for Good Clinical Practice, and applicable region-specific regulatory requirements. Study protocol and amendments were reviewed by independent ethics committees and institutional review boards at each center.
: All patients provided written informed consent.
: Not applicable.
: The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at ExternalRef removed. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at ExternalRef removed.